Laura A. Philips, PhD, MBA, is a Board Member and independent consultant for early stage companies. She serves on the Board of Directors of Delcath System (NASDAQ:DCTH) a biotech company developing chemosaturation treatments for cancer in the liver; WellGen, Inc., a nutrigenomics company developing medicinal foods for the health and wellness markets; Boyce Thompson Institute a biological research institute associated with Cornell University; and Americans for UNFPA a UN organization that promotes health care and the rights of women around the world. From 2010-2011 Dr. Philips served on the board of directors of China Yongxin Phamaceuticals (OTCBB:CYXN) a leading retailer, wholesaler and distributor of pharmaceuticals and health and beauty products in Northeastern China. From 2003-06 Dr. Philips was Chief Operating Officer and Chief Financial Officer at NexGenix Pharmaceuticals, a niche pharmaceutical start-up company. Prior to joining NexGenix, she was Vice President at AMDeC, a biomedical research and development consortium in New York. She held a variety of executive positions at Corning, Incorporated, from 1997-2002 including director of product development, strategic planning and business manager. Dr. Philips served in the Clinton Administration in both the White House Office of Science and Technology Policy and as Senior Policy Advisor to Sec. Ronald Brown in the Dept. of Commerce. She was Congressional Science Fellow and Legislative Advisor for Technology Policy to Sen. Joseph Lieberman in 1994-5. Dr. Philips was on the Faculty of Cornell University in the Dept of Chemistry from 1987-1993. During 1985 – 1987 she was an NIH Post-Doctoral Fellow at the University of Chicago in the Department of Chemistry. She holds a PhD in Chemistry from the University of California, Berkeley and an MBA from Cornell University.